Table 2. Investigational therapies in... | American Society of Hematology

Table 2.

Investigational therapies in R/R cHL

Agent	Study design	Median age (range), years	Total (N)	Prior AHCT (n)	ORR% (CR%)	Median PFS/EFS (mo)	Reference
Cami	I^*	38 (31-53)	57	NR	75 (44)	NR	Hamadani et al²²
Cami	II	36 (20-74)	51	31	83 (38)	NR	Herrera et al²³
Everolimus	II	32 (19-77)	57	38	46 (9)	8	Johnston et al²⁵
Lenalidomide	II	37 (18–74)	15	10	13	NR	Kuruvilla et al²⁸
Lenalidomide	II	38 (20–83)	42	31	30	8.2	Fehniger et al²⁹
Vorinostat	II	42 (20-71)	25	11	4	7.2	Kirschbaum et al³²
Panobinostat	II	32 (18-75)	129	129	27 (4)	6.9	Younes et al³³
Idelalisib	II	42 (21-80)	25	18	20 (4)	2.3	Gopal et al⁵¹
Ibrutinib^†	Retrosp	35 (26-72)	7	5	57 (43)	NA	Badar et al⁵²

Agent	Study design	Median age (range), years	Total (N)	Prior AHCT (n)	ORR% (CR%)	Median PFS/EFS (mo)	Reference
Cami	I^*	38 (31-53)	57	NR	75 (44)	NR	Hamadani et al²²
Cami	II	36 (20-74)	51	31	83 (38)	NR	Herrera et al²³
Everolimus	II	32 (19-77)	57	38	46 (9)	8	Johnston et al²⁵
Lenalidomide	II	37 (18–74)	15	10	13	NR	Kuruvilla et al²⁸
Lenalidomide	II	38 (20–83)	42	31	30	8.2	Fehniger et al²⁹
Vorinostat	II	42 (20-71)	25	11	4	7.2	Kirschbaum et al³²
Panobinostat	II	32 (18-75)	129	129	27 (4)	6.9	Younes et al³³
Idelalisib	II	42 (21-80)	25	18	20 (4)	2.3	Gopal et al⁵¹
Ibrutinib^†	Retrosp	35 (26-72)	7	5	57 (43)	NA	Badar et al⁵²

^*

Data shown for 30 µg/kg and 45 µg/kg cohorts.

A clinical trial is ongoing investigating the role of ibrutinib in R/R cHL (NCT02824029).

NA, not applicable; NR, not reported; Retrosp, retrospective.